Cargando…

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

BACKGROUND: Prevalence and distribution of pathogenetic mutations in BRAF and NRAS genes were evaluated in multiple melanoma lesions from patients with different geographical origin within the same Italian population. METHODS: Genomic DNA from a total of 749 tumor samples (451 primary tumors and 298...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colombino, Maria, Lissia, Amelia, Capone, Mariaelena, De Giorgi, Vincenzo, Massi, Daniela, Stanganelli, Ignazio, Fonsatti, Ester, Maio, Michele, Botti, Gerardo, Caracò, Corrado, Mozzillo, Nicola, Ascierto, Paolo A, Cossu, Antonio, Palmieri, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765741/ https://www.ncbi.nlm.nih.gov/pubmed/23987572 http://dx.doi.org/10.1186/1479-5876-11-202

Ejemplares similares

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma
por: Colombino, Maria, et al.
Publicado: (2014)

Discrepant alterations in main candidate genes among multiple primary melanomas
por: Colombino, Maria, et al.
Publicado: (2014)

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study
por: Casula, Milena, et al.
Publicado: (2019)

Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients
por: Colombino, Maria, et al.
Publicado: (2020)

Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach
por: Manca, Antonella, et al.
Publicado: (2019)

Genetic alterations in main candidate genes during melanoma progression
por: Sini, Maria Cristina, et al.
Publicado: (2018)

BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas
por: Colombino, Maria, et al.
Publicado: (2019)

Immunoscore: a new possible approach for melanoma classification
por: Capone, Mariaelena, et al.
Publicado: (2014)

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
por: Palmieri, Giuseppe, et al.
Publicado: (2017)

Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2012)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
por: Gentilcore, Giusy, et al.
Publicado: (2013)

Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases
por: Palmieri, G, et al.
Publicado: (2000)

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
por: Caracò, Corrado, et al.
Publicado: (2013)

Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy
por: Casula, Milena, et al.
Publicado: (2009)

Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors
por: Mozzillo, Nicola, et al.
Publicado: (2013)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Primary Dermal Melanoma in a Patient with a History of Multiple Malignancies: A Case Report with Molecular Characterization
por: Sini, Germana, et al.
Publicado: (2013)

Resection in the popliteal fossa for metastatic melanoma
por: Marone, Ugo, et al.
Publicado: (2007)

Do BRAF inhibitors select for populations with different disease progression kinetics?
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment
por: Ascierto, Paolo A, et al.
Publicado: (2010)

Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspective
por: Ombra, Maria Neve, et al.
Publicado: (2019)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
por: Simeone, Ester, et al.
Publicado: (2015)

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2006)

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
por: Palomba, Grazia, et al.
Publicado: (2016)

Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave
por: Atripaldi, Luigi, et al.
Publicado: (2021)

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2014)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a (V600E)BRAF inhibitor): a case report
por: Simeone, Ester, et al.
Publicado: (2012)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

New paradigm for stage III melanoma: from surgery to adjuvant treatment
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi
por: Francis, Jasmine H., et al.
Publicado: (2018)

Main roads to melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2009)

Vitamin D status and risk for malignant cutaneous melanoma: recent advances
por: Ombra, Maria N., et al.
Publicado: (2017)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
por: Ascierto, Paolo A, et al.
Publicado: (2012)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
por: Tschandl, Philipp, et al.
Publicado: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
por: Chiappetta, Caterina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4liqiennpgf600vkemrcjhoeme